Absci Corp (ABSI)
Healthcare
Biotechnology
7.80 $
+1.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Absci Corp (ABSI)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.9% of the shares are freely tradable; institutional investors hold 72.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
72.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
12.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
87.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
26.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
169Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.51 | 22,550,997 | +0.8 | 03/31/2026 |
| ARK Investment Management LLC | 8.83 | 13,726,169 | +9.4 | 03/31/2026 |
| BlackRock Inc | 7.24 | 11,255,194 | -0.7 | 03/31/2026 |
| Redmile Group, LLC | 5.31 | 8,253,316 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 5.09 | 7,910,205 | +8.6 | 12/31/2025 |
| State Street Corp | 4.71 | 7,324,858 | +22.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARK Genomic Revolution | 7.21 | 11,201,282 | -3.0 | 03/31/2026 |
| ARK Genomic Revolution ETF | 6.99 | 10,867,543 | -0.3 | 05/31/2026 |
| Fidelity Growth Compy Commingled Pl S | 6.64 | 10,323,449 | +3.8 | 04/30/2026 |
| Fidelity Growth Company Fund | 4.63 | 7,190,470 | +4.1 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.